Skip to content

Low Fructose Diet in Diabetes Type 2

Effects of Low Fructose Diet on Glycemic Control in Patients With Type 2 Diabetes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03352596
Enrollment
48
Registered
2017-11-24
Start date
2017-01-01
Completion date
2017-11-30
Last updated
2017-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fructose Metabolism Disorder

Brief summary

Diabetes is one of the most common and chronic diseases in the world, with the prevalence and incidence of this disease rising in most societies, especially in Iran. Suitable treatments for type 2 diabetes include changing lifestyle with exercise, nutrition, and drug use. New research suggests that added sugar, especially fructose, is the main trigger for diabetes and pre-diabetes even more potent than other carbohydrates. Fructose has a low glycemic index (23μg =) and slowly increases blood glucose levels. Therefore, it is thought that replacing fructose instead of glucose can have a positive effect on glycemic control of diabetic patients..

Interventions

OTHERlow frutose diet

Sponsors

National Nutrition and Food Technology Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Age of 70-40 years 2. body mass index(BMI) between 18.5 and 27 3. Type 2 diabetes People who only control their diabetes by using glucose lowering tablets Type 2 diabetes (1 to 10 years)

Exclusion criteria

1. Pregnancy and lactation 2. Thyroid gland disorders 3. Kidney disease and inflammation 4. Follow the weight loss regimen 6 months before starting the study 5. Usage of fatty and fatty foods, fiber powder Vitamin A Mineral Supplements, Omega 3 6. Taking glucocorticoid drugs and non-steroidal anti-inflammatory drugs

Design outcomes

Primary

MeasureTime frame
fasting blood suger(FBS)8 weeks
Homeostatic model assessment and insulin resistance(HOMA-IR)8weeks
insulin8 weeks

Secondary

MeasureTime frame
HDL-C8 weeks
Triglyceride8 weeks
Blood pressure8 weeks
Total cholestrole8 weeks
LDL-C8 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026